Matuzumab

Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab[1].

Product Specifications

CAS Number

[339186-68-4]

Product Name Alternative

EMD 72000

UNSPSC

12352203

Target

EGFR

Type

Inhibitory Antibodies

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/matuzumab.html

Purity

99.0

Solubility

H2O

Smiles

[Matuzumab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]Joan H Schiller. Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000) . Cancer Invest. 2008 Feb;26 (1) :81-95.|[2]Bier H, et al. Anti- (epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother. 1998 May;46 (3) :167-73.